Health Care Equipment

Aethlon Medical

Aethlon Medical Inc. Completes Private Placement of Shares and Warrants

Maxim Group Analyst Reiterates Hold Rating on Aethlon Medical

Aethlon Medical released FY2026 Semi-Annual earnings on November 12, 2025, After-Market EST, with actual revenue USD 0 and EPS USD -10.6537

Aethlon Medical released FY2026 Q2 earnings on November 12 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -3.741 (forecast USD -3.6633)

Aethlon Medical to Release FY2026 Q2 Earnings on November 12 After-Market EST, Forecast Revenue USD 0, EPS USD -3.6633

Aethlon Medical released FY2026 Q1 earnings on August 13 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.85 (forecast USD -0.86)

Aethlon Medical to Release FY2026 Q1 Earnings on August 13 After-Market EST, Forecast EPS USD -0.86

Aethlon Medical Advances Blood Purifier Clinical Trial

Aethlon Medical released FY2025 Q4 earnings on June 27 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -34.41 (forecast USD -10.9)

Aethlon Medical released FY2025 annual earnings on June 27 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -85.7748 (forecast USD -58.2)

Aethlon Medical's Hemopurifier® Cancer Clinical Trial Approved by Indian Regulatory Authorities

Aethlon Medical Plans to Release Quarterly Earnings Report

Aethlon Medical Inc forecasts a loss of $1.01 per share

Aethlon Medical Reports Q4 2025 Financial Results

Aethlon Medical to Release FY2025 Q4 Earnings on June 26 After-Market EST, Forecast EPS -1.09 USD

Aethlon Medical Reports Hemopurifier Cancer Trial Progress

Aethlon Medical Inc. Poster Abstract on Long COVID Research Accepted

Aethlon Medical Oncology Clinical Trial Confirmed

Aethlon demonstrates Hemopurifier's capability to remove platelet-derived extracellular vesicles

Aethlon Medical released FY2025 Q3 earnings on February 12 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -10.0544 (forecast USD -16.2666)

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap